Galloway et al. reported that the major issue with TNFα-blockers has been an increased risk of bacterial and fungal superinfections [137], which can be a cause of concern in COVID-19 patients, who as documented by Zhou et al., mostly suffer superadded lung infections due to pre-existing foci [138]. The gene discussed is TNF; the disease is COVID-19.